Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin

Leukemia. 2003 Feb;17(2):468-70. doi: 10.1038/sj.leu.2402749.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides*
  • Anti-Bacterial Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / blood*
  • Antigens, Differentiation, Myelomonocytic / blood*
  • Child
  • Child, Preschool
  • Chromosome Deletion
  • Female
  • Gemtuzumab
  • Humans
  • Immunotoxins / therapeutic use*
  • Infant
  • Karyotyping
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD33 protein, human
  • Immunotoxins
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab